• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis 
    •   QMRO Home
    • Blizard Institute
    • Centre for Neuroscience, Surgery and Trauma
    • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
    •   QMRO Home
    • Blizard Institute
    • Centre for Neuroscience, Surgery and Trauma
    • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    View/Open
    Published version (292.1Kb)
    Volume
    376
    Pagination
    209 - 220
    DOI
    10.1056/NEJMoa1606468
    Journal
    NEW ENGLAND JOURNAL OF MEDICINE
    Issue
    3
    ISSN
    0028-4793
    Metadata
    Show full item record
    Authors
    Montalban, X; Hauser, SL; Kappos, L; Arnold, DL; Bar-Or, A; Comi, G; de Seze, J; Giovannoni, G; Hartung, H-P; Hemmer, B
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/18928
    Collections
    • Centre for Neuroscience, Surgery and Trauma [991]
    Licence information
    From New England Journal of Medicine, Montalban X, et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, 376:209-220. DOI: 10.1056/NEJMoa1606468. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission.
    Copyright statements
    Copyright © 2016 Massachusetts Medical Society. All rights reserved.
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.